Project Grant R44CA250616
Award Date
7/15/20
Completion Date
7/31/25
Dollars Obligated
$3.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Avon, CT 06001, USA
Similar Awards
This $269,280 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Cold Spring Harbor Laboratory (CSHL) to develop a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The key objectives are to determine the selectivity of jerantinine alkaloid-mediated covalent modification of K-RAS(G12C) and evaluate if this can lead to targeted protein degradation, while also leveraging the inherent cytotoxic effects of the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Tigatx Inc., a small business in Boston, MA, provides $1,418,424 in funding to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers, including non-small cell lung cancer (NSCLC). The primary objective is to develop a first-in-class IgA-based monoclonal antibody treatment, TIGA-001, and progress it through CMC...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,013,623 to March Biosciences Inc. to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The key objectives are to engineer partially-matched, donor-derived CAR T-cells targeting the CD5 and CD7 antigens, which are expressed on most T-cell...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $503,194 to Seattle Children's Hospital (doing business as Seattle Children's Research Institute) to assess the efficacy of a multispecific T cell engager (MTE) therapy in treating neuroblastoma. The key products/services to be delivered under this 2-year award (9/1/2024 - 8/31/2026) include: Determining the vulnerability of patient-derived neuroblastoma samples to the MTE...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) totaling $352,275 provides funding to the Regents of the University of Minnesota to conduct research aimed at developing novel, safe, and effective agents for the prevention and therapy of lung cancer with co-occurring KRAS and LKB1 mutations. The key objectives are to: Assess the safety and efficacy of MITOMET, a mitochondria-targeted metformin analog, in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at improving treatment for cancers driven by KRAS mutations. The primary objectives are to: Evaluate four serine/threonine kinase family members as potential synthetic lethal targets to enhance the efficacy of KRAS inhibitor therapies, and clarify the underlying mechanisms. Use CRISPR/Cas9...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy targeting the MR1 protein for the treatment of acute myeloid leukemia (AML) and glioblastoma. The key objectives are to 1) assess MR1 expression in primary AML and glioblastoma samples, 2) evaluate the efficacy of the MR1 CAR-T cells in mouse tumor models, and 3) assess the safety of the MR1 CAR-T cells. The proposed work...
This $528,175 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by H. Lee Moffitt Cancer Center and Research Institute to identify novel cell surface targets for immunotherapies to treat multiple myeloma. The key objectives are to: Define the expression patterns of six promising target antigens (SEMA4A, ILT3, CCR1, LRRC8D, FCRL3, IL12RB1) in primary myeloma cells from high-risk relapsed patients, and assess their suitability...
This federal Project Grant award of $399,669.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for the treatment of glioblastoma (GBM), the most common and deadly primary brain cancer. The key products/services to be delivered under this award include: Developing a platform to generate potent and personalized GBM-specific T cells in an...